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Abstract  26 
Carbapenemase-producing Enterobacterales expressing OXA-48, KPC, NDM, VIM or IMP 27 
enzymes are increasingly reported worldwide. We have characterized LMB-1, a novel metallo-β-28 
latamase (MBL) of Ambler class B3 from Citrobacter freundii 164 (Cf164) clinical isolate from Buenos 29 
Aires, Argentina. 30 
Cf164 displayed reduced susceptibility to carbapenems but gave inconsistent results with 31 
carbapenemase confirmatory tests, suggesting the presence of a weak carbapenemase. Analysis of WGS 32 
of Cf164 using Resfinder revealed four β-lactamase genes coding for CTX-M-8, PER-2, TEM-1 and 33 
CMY-150, a novel chromosomally-encoded CMY variant. Kinetic parameters of purified CMY-150 did 34 
not reveal any carbapenemase activity. However, CMY-150 conferred to E. coli higher MIC values for 35 
ceftazidime and aztreonam as compared to CMY-2. The in-house developed β-lactamase search 36 
software (ResMINER) in WGS data, revealed a novel subclass B3 MBL named LMB-1. LMB-1 37 
conferred to E. coli, resistance to penicillins, to expanded-spectrum cephalosporins and reduced 38 
susceptibility to carbapenems. The blaLMB-1 gene was located on a 176-kb IncA/C2 plasmid. LMB-1 39 
shared 99% of amino acid sequence identity with the MBL encoded in the chromosome of 40 
Rheinheimera pacifica, it’s likely progenitor. Despite repeated attempts, LMB-1 could not be purified, 41 
thus only specific activities could evidence hydrolysis of carbapenems. 42 
Here we report CMY-150, a novel CMY-2 variant that confers increased ceftazidime and 43 
aztreonam MICs to E. coli and the first description of LMB-1 in Argentina. This work underlines the 44 
need for several CPE confirmatory tests, as this novel enzyme might have been missed using only one. 45 
46 
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1. Introduction 47 
Gram-negative bacteria (GNB), especially Enterobacterales, Pseudomonas aeruginosa and 48 
Acinetobacter baumannii, have re-emerged as major players in antimicrobial resistance worldwide. In 49 
these species, resistance may affect all major classes of anti-gram-negative agents, the multidrug 50 
resistance (MDR) being relatively common. Currently, β-lactamase-mediated resistance does not spare 51 
even the newest and most powerful β-lactams (carbapenems), whose activity is challenged by 52 
carbapenemases [1].  53 
Carbapenem-hydrolyzing -lactamases encountered in Enterobacterales belong either to (i) the 54 
Ambler class A including KPC, IMI and GES enzymes, (ii) Ambler class B metallo--lactamases (or 55 
MBL) of NDM-, VIM- and IMP-type, and (iii) Ambler class D enzymes including OXA-48 and its 56 
variants (mostly OXA-181, OXA-204 and OXA-232) [1]. Even though described for a few class C 57 
enzymes, carbapenem-hydrolysis is very rare and weak [2,3]. 58 
MBLs are by far the most worrisome β-lactamases since their prevalence is increasing worldwide, 59 
their broad substrate profile (including all β-lactams, except monobactams), and the lack of clinically-60 
useful inhibitors. The MBLs are divided into three subclasses (B1, B2, B3) based on primary amino 61 
acid sequence homology [4]. There is relatively low sequence identity (< 20%) between the subclasses. 62 
Within a subclass the sequence identity is higher and this, along with distinctive structural 63 
characteristics within the active sites of B1, B2, and B3 enzymes, is the basis for the establishment of 64 
the three subclasses. The B1 and B3 subclasses have a broad-spectrum substrate profile that includes 65 
penicillins, cephalosporins, and carbapenems and contain two Zn2+ ions in their active site, while the B2 66 
enzymes exhibit a narrow-spectrum profile that includes carbapenems and contain only one Zn2+ion.  67 
MBLs of subclass B1, such as NDM, VIM, and IMP-like are the clinically-most relevant enzymes 68 
in Enterobacterales, but sporadic isolations of other class B1 MBLs such as GIM, FIM, KHM, have also 69 
be reported [4]. Subclass B2 contains only two enzymes that possess a narrow-spectrum of hydrolysis. 70 
The Subclass B3 is a larger group of enzymes, of which the genes are mostly chromosomally-encoded, 71 
and display a broad-spectrum of ß-lactam hydrolysis. In this subclass only AIM, found in P. 72 
aeruginosa, and SMB-1 in Serratia marcescens have been reported acquired [5,6]. 73 
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While the increasing availability of commercial qPCR systems allows for the detection of the 74 
most prevalent MBL families, molecular diagnostics clearly overlooks MBLs that belong to less 75 
prevalent MBL-families. Furthermore, novel MBLs have recently been identified in clinical isolates: 76 
TMB-1 in Enterobacter hormaechei and Citrobacter freundii from Tunisia [7] and LMB-1 in 77 
Enterobacter cloacae from Austria [8]. In this work, we have characterized a novel chromosomally-78 
encoded CMY-variant: CMY-150 and the second clinical LMB-1-producing Enterobacterales, a C. 79 
freundii clinical isolate recovered from a Hospital in Buenos Aires, Argentina.  80 
2. Materials and Methods 81 
2.1. Bacterial strains. C. freundii 164 (Cf164) was identified with matrix-assisted laser 82 
desorption ionization–time of flight (MALDI-TOF) mass spectrometry (MALDI Biotyper CA system, 83 
Bruker Daltonics, Billerica, MA, USA). Escherichia coli TOP10 (Invitrogen, Saint-Aubin, France) was 84 
used for cloning experiments and E. coli BL21 was used for over-expression of ß-lactamases.   85 
2.2. Antimicrobial agents, susceptibility testing. Antimicrobial susceptibilities were 86 
determined by disk diffusion on Mueller-Hinton agar (Bio-Rad, Marnes-La-Coquette, France) and 87 
interpreted according to the EUCAST breakpoints, updated in 2018 (http://www.eucast.org). Minimal 88 
inhibitory concentration (MIC) values were determined using the Etest technique (BioMérieux, Marcy-89 
l’Etoile, France). 90 
2.3. Confirmatory tests for carbapenemase-producing Enterobacteria. Carbapenemase 91 
activity was investigated using the in house Carba NP test, Blue Carba, Modified Hodge test, β Carba 92 
Test (BioRad, Marnes-la-Coquette, France), rCIM, Maldi-TOF (MBT STAR-CarbaTM, Brucker), PCRs 93 
and NG Carba5 (NG Biotech, Rennes, France) tests were performed following the manufacturer’s 94 
recommendations or as previously published [9-12]. 95 
2.4. PCR, cloning experiments, and sequencing. Whole-cell DNAs of Cf164 isolates were 96 
extracted using the QIAamp DNA minikit (Qiagen, Les Ulis, France) and were used as templates for 97 
PCR with the following primers: preCMY-150-A (5’-ATGATGAAAAAATCGAT-3’) and preCMY-98 
150-B (5’-TCTGTCAGTTATTGCAGT-3’) and preLMB-1-A (5’-ATGACGTTAGCTAAAAGTTTT -99 
3’) and preLMB-1-B (5’-TACTGCGTTGTTTCCTTTATTAAA-3’) from amplifying blaCMY-150, and 100 
blaLMB-1, respectively. The amplicon obtained was then cloned into the pCR®-Blunt II-TOPO® plasmid 101 
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(Invitrogen) downstream from the pLac promoter, in the same orientation. The recombinant pR-CMY-102 
150 and pR-LMB-1 plasmids were electroporated into the E. coli TOP10 strain; the electroporants were 103 
plated on TSA plate containing kanamaycin (50 µg/ml).  104 
The blaCMY-150 and blaLMB-1 gene fragments corresponding to the mature β-lactamases were 105 
cloned into the expression vector pET41b (+) (Novagen, VWR International, Fontenay-sous-Bois, 106 
France) and blaLMB-1 gene fragment corresponding to the mature β-lactamases was also cloned into 107 
pET28a (Novagen) using the PCR generated fragment with primers CMY-150-Mat (5’-108 
ACTTTAAGAAGGAGATATACATATGAAAACAGAACAACAAATTGCCGA-3’) and CMY-150-109 
Stop (5’-TGGTGGTGGTGCTCGAATTGCAGTTTTTCAAGAATGCGC-3’), LMB-1-pET41b_Fw 110 
(5’-TTTACTTCCAGGGCCAAGGAATGCTGGCCGGTTGC-3’), LMB-1-pET41b-Rv (5’-111 
TGGTGGTGGTGGTGGTGCTCGATTACTGCGTTGTT-3’), LMB_pET28a_Fw (5'-112 
TTTACTTCCAGGGCCAAGGAATGCTGGCCGGTTGC-3'), LMB_pET28a_Rv (5'-113 
TGGTGGTGGTGGTGGTGCTCGATTACTGCGTTGTT 3') and the NEBuilder® HiFi DNA 114 
Assembly Cloning Kit (New England BioLabs, Ozyme, Les Ulis, France), following the manufacturer’s 115 
instructions. The recombinant plasmids pET41-CMY-150 pET41b-LMB-1 and pET28a-LMB-1 were 116 
transformed into the chemically-competent E. coli strain BL21 (DE3).  117 
Recombinant plasmids were extracted using the Qiagen miniprep kit and both strands of the 118 
inserts were sequenced using M13 primers for the pCR®-Blunt II-TOPO® plasmid (Invitrogen), and 119 
T7 primers for pET41b(+) (Novagen), with an automatic sequencer (ABI Prism 3100; Applied 120 
Biosystems, Les Ulis, France). The nucleotide sequences were analyzed using software available at the 121 
National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov). 122 
2.5. Whole genome sequencing (WGS) and Bioinformatic analysis. Total DNA was 123 
extracted from colonies using the Ultraclean Microbial DNA Isolation Kit (MO BIO Laboratories, 124 
Carlsbad, CA, US) following the manufacturer’s instructions. The DNA concentration and purity were 125 
controlled by a Qubit® 2.0 Fluorometer using the dsDNA HS and/or BR assay kit (Life technologies, 126 
Carlsbad, CA, US). The DNA library was prepared using the Nextera XT-v3 kit (Illumina, San Diego, 127 
CA, US) according to the manufacturer’s instructions and then run on Miseq (Illumina) for generating 128 
paired-end 2x150 bp reads. De novo assembly was performed by CLC Genomics Workbench v9.5 129 
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(Qiagen) after quality trimming (Qs ≥ 20) according the manufacturer’s recommendations (Qiagen, 130 
Courtaboeuf, France). C. freundii Cf164 total DNA was also sequenced using PacBio long read 131 
technology (Macrogen, Seoul, South Korea). PacBio subreads were assembled with both Canu [13] and 132 
the RS_HGAP_Assembly.3 protocol from the SMRT analysis toolkit v2.3, while consensus accuracy 133 
was further polished using Quiver [14] as was previously described [15]. The acquired antimicrobial 134 
resistance genes were identified by uploading assembled genomes to the Resfinder server v2.1 that uses 135 
BLAST for identification of acquired antimicrobial resistance genes and chromosomal mutations in 136 
whole-genome data (http://cge.cbs.dtu.dk/services/ResFinder-2.1) [16]. Additionally, the whole genome 137 
sequence of Cf164 was also uploaded to an in-house developed software, ResMiner (BI Iorga, pers. 138 
comm.), that searches for flags specific of the four molecular classes of β-lactamases.  139 
For the reconstruction of pCf164_LMB-1 and pCf164_CTX-M-8 gaps were filled by PCR 140 
amplification and Sanger sequencing. Open reading frames (ORFs) were annotated using the RAST 141 
server (rast.nmpdr.org) followed by manual comparative curation and determination of sequence 142 
similarity using the BLAST web server. Alignments were performed by using the BRIG tool [17] 143 
2.6. Plasmid characterization and conjugation assay. Plasmid DNA of the clinical isolates 144 
Cf164 was extracted using the Kieser method [18]. The Kieser extract was used to transform E. coli 145 
TOP10 strain by electroporation. The electroporants were plated on a TSA plate containing 100 µg/ml 146 
ampicillin. Transformants were analyzed by PCR using the primers pre-LMB-1A and pre-LMB-1B. 147 
From the transformants harboring the blaLMB-1 gene, plasmid DNA extraction was done using the 148 
Kieser’s method and subsequently analyzed on 0.7% agarose gel stained with ethidium bromide. 149 
Plasmids of ca. 154, 66, 48, and 7 kb of E. coli NCTC 50192 were used as plasmid size markers [19].   150 
To perform the quantitative filter mating-out assay, the clinical isolates Cf164 was used as 151 
donor and E. coli J53 as recipient. Both isolates were each grown overnight in brain heart infusion 152 
(BHI) (BioMérieux). A 0.25 ml of each donor and recipient donor culture were diluted in 4.75 ml BHI 153 
broth and incubated at 37°C for 5 h without shaking. Subsequently, 0.25 ml of the donor culture was 154 
gently mixed with 2.5 ml of the recipient culture, and 200 µl of this mating mix was spotted on a 0.45-155 
µm filter (Millipore, Paris, France) placed on a prewarmed MH plates and incubated at 37°C for 2 h. 156 
The mating assays were terminated by placing the filters in 4 ml of an ice-cold 0.9% NaCl solution, 157 
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followed by vigorous agitation for 30 s. The number of transconjugants per donor cell was determined 158 
by plating dilutions of the mating mixture onto plates containing antibiotics. Strain donor cells were 159 
selected with 100µg /ml ampicillin. Transconjugants were selected with 100µg/ml ampicillin and 160 
100µg/ml azide. Transfer frequencies were calculated by dividing the number of transconjugants by the 161 
number of donor cells.  162 
2.7. β-Lactamase purification. An overnight culture of E. coli strain BL21 (DE3) harboring 163 
pET41b-CMY-150, pET41b-LMB-1 and pET28a-LMB-1 were used to inoculate 2 L of LB broth 164 
containing 50 µg/ml kanamycin. The bacteria were cultured at 37ºC until reaching an OD of 0.6 at 600 165 
nm. Expression of both enzymes was induced overnight at 25ºC with 0.2 mM IPTG, as previously 166 
described [20]. For pET41b-LMB-1 additional induction conditions were tested (temperature: 16°, 25°, 167 
37°; IPTG: 0.2mM, 0.5mM, 1.0mM; cells: E. coli BL21 (DE3), E. coli BL21 (DE3) pLysS, 168 
E. coli Rosetta™ (DE3)). Cultures were centrifuged at 6000 g for 15 min and the pellets were 169 
resuspended in 10 mL of Buffer A (20 mM phosphate buffer, 175 mM potassium sulfate (K2SO4), 170 
40mM Imidazol, pH 7.40). The cells were disrupted by sonication and bacterial debris was removed by 171 
two consecutive centrifugation steps: at 10.000 g for 1 h at 4ºC, and at 48.000 g for 1 h at 4ºC. CMY-172 
150 and LMB-1 were purified in one step pseudo-affinity chromatography using a NTA-Ni column (GE 173 
Healthcare, Les Ulis, France) [20]. Protein purity was estimated by SDS-PAGE, pure fractions were 174 
pooled and dialyzed against 20mM Hepes, K2SO4 50mM buffer (pH 7) and concentrated using 175 
Vivaspin® columns (GE Healthcare). Protein concentration was determined by Bradford Protein assay 176 
(Bio-Rad) [20]. 177 
2.8. Steady-state kinetic parameters. Kinetic parameters of purified CMY-150 were 178 
determined at 30ºC in 100mM sodium phosphate buffer (pH 7). The kcat and Km values were determined 179 
by analyzing hydrolysis of β-lactams under initial-rate conditions with an ULTROSPEC 2000 model 180 
UV spectrophotometer (GE Healthcare) using the Eadie–Hoffstee linearization of the Michaelis–181 
Menten equation, as previously described [20]. The different β-lactams were purchased from Sigma–182 
Aldrich (Saint-Quentin-Fallavier, France).  183 
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The specific activities of the -lactamase LMB-1 for β-lactams were determined on the 184 
supernatant of a whole cell crude extract obtained from an overnight culture of pTOPO-LMB-1 in E. 185 
coli TOP 10 as previously described [19].  186 
2.9. Nucleotide sequence accession number. The whole genome sequence of Cf164 generated 187 
in the study have been submitted to the Genbank nucleotide sequence database, under the accession 188 
number of NZ_QCWX01000001. The nucleotide sequence of blaCMY-150 genes along with plasmid 189 
pCf164_LMB-1 and pCf164_CTX-M-8 have been submitted to the EMBL/Genbank nucleotide 190 
sequence database under the accession numbers NG_060513, MH475146 and MN187903, respectively. 191 
 192 
 193 
3. Results and discussion 194 
3.1. Clinical case. A 68-year-old patient with Non-Hodgkin lymphoma, type l diabetes and 195 
history of previous myocardial infarction, was admitted in a tertiary care hospital in Buenos Aires. After 196 
12 days of the hospitalization, he presented febrile neutropenia and a catheter-related bacteraemia due 197 
to a methicillin resistant Staphylococcus haemolyticus. At the same time, the urine culture revealed a 198 
bacterial count of 105 CFU/ml of a C. freundii isolate. The patient was treated with vancomycin and 199 
amikacin that led to the resolution of the urinary tract infection and the bacteraemia. 200 
3.2. Characteristics of C. freundii 164. Routine antibiogram and MIC values of Cf164 201 
revealed penicillins, aztreonam, expanded-spectrum cephalosporin resistance and reduced susceptibility 202 
to imipenem (Table 1). As the MIC for imipenem was 0.5 µg/ml and even though the MIC for 203 
meropenem was below 0.125 µg/ml, which is the EUCAST screening cut off for carbapenemases, the 204 
blue carba carbapenemase confirmatory test was performed. The latter gave a weak positive result 205 
suggesting the presence of a carbapenem-hydrolyzing β-lactamase. These results were confirmed using 206 
different biochemical confirmatory tests based on imipenem hydrolysis (β Carba, rCIM and MBT 207 
STAR-CarbaTM tests) which were consistently positive except for the Carba NP that remained 208 
repeatedly negative. PCRs detecting the five most prevalent carbapenemases (blaOXA-48, blaKPC, blaNDM, 209 
blaVIM, blaIMP) and the immunochromatographic NG Carba5 test were negative, suggesting the presence 210 
of a minor carbapenemase. WGS data of Cf164 was analyzed using CLC genomic workbench (Qiagen) 211 
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and revealed a genome of 5,229,602 bp, with an average 50 X coverage (NZ_QCWX01000001). 212 
Resistome was analyzed by searching acquired genes using Resfinder and point mutations involved in 213 
chromosomal resistance. Four β-lactamase genes were identified, a novel chromosomal and natural 214 
blaCMY-2-like gene, blaCTX-M-8 and blaPER-2 coding for two ESBLs, and blaTEM-1, coding for a broad-215 
spectrum penicillinase. The isolate harbored also two qnr resistance genes (qnrE and qnrB38), a 216 
rifampicin resistance gene (aar-3), a sulfonamide resistant gene (sul1) and a trimethoprim resistance 217 
gene (dfrA27). The finding of these genes matched well with the resistance phenotype of Cf164 to 218 
trimethoprim and to nalidixic acid. Mutations in the QRDR, known to confer fluoroquinolone resistance 219 
were not found explaining the susceptibility to fluoroquinolones. 220 
3.3. Characterization of β-lactamase CMY-150. CMY-150 differs from CMY-2 by 15 amino- 221 
acid substitutions (L6I, V52I, Q55E, Q122R, R125S, R146T, A150E, H153R, A182V, P185H, N214S, 222 
D218N, H262L, A273E, V368A) and for CMY-65 by two amino-acid substitutions (P185H, H262L). 223 
CMY-150 and CMY-2 were cloned into the pCR®-Blunt II-TOPO® plasmid (pTOPO-CMY-150, and 224 
pTOPO-CMY-2) and transformed into E. coli TOP10. CMY-150 conferred a higher level of resistance 225 
to cefotaxime (>256 µg/ml vs 8 µg/ml for CMY-2), ceftazidime (>256 µg/ml vs 24 µg/ml for CMY-2) 226 
and aztreonam (32 µg/ml vs 3 µg/ml for CMY-2) (Table 1). MICs for carbapenems were 227 
heterogeneous, with imipenem being the highest (MIC 0.38 µg/ml), meropenem (MIC 0.047 µg/ml) and 228 
ertapenem (MIC 0.047 µg/ml) remaining in the susceptibility range. The MICs for carbapenems 229 
conferred by pTOPO-CMY-150, even though in the susceptibility range, were slightly higher than those 230 
conferred by CMY-2 (Table 1). In front of these results, MICs for imipenem for Cf164 was performed 231 
on cloxacillin-containing (250 µg/ml) MH plates and revealed the exact same value, suggesting that 232 
another enzyme capable of hydrolyzing carbapenems might be present in these bacteria. 233 
To compare the kinetic properties of CMY-2 and the new CMY-150, the steady state 234 
parameters of the pure proteins were determined (Table2). Overall, the catalytic efficiencies were very 235 
similar between the two enzymes, except for ampicillin (40-fold higher for CMY-2). The kinetic 236 
parameters for aztreonam could not be obtained since no hydrolysis was observed. For this reason,  we 237 
determined the IC50 values for CMY-2 and CMY-150, revealing similar results for both enzymes (0.2 238 
µM for CMY-2 and 0.31 µM for CMY-150). These results cannot explain the difference observed in 239 
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the MIC values obtained and although further analysis are required to understand this phenotype, we 240 
suggest that the CMY-150 could present a higher affinity for aztreonam than CMY-2. Regarding the 241 
kinetic parameters for imipenem, in both enzymes the Km values were highly similar as well as the 242 
activity, further suggesting that another enzyme capable of hydrolyzing carbapenems might be present 243 
in Cf164. 244 
3.4. Identification of blaLMB-1 gene in the WGS of Cf164. Using an in-house developed 245 
software, ResMiner (BI Iorga, pers. comm.), that searches for flags specific of the four molecular 246 
classes of β-lactamases, found in addition to blaCMY-150, blaCTX-M-8, blaPER-2 and blaTEM-1 genes, an 247 
additional gene coding for a putative MBL of sub class B3. Blast searches revealed that this MBL had 248 
100 % sequence identity with LMB-1, a MBL found only once if an E. cloacae isolate from Linz in 249 
Austria (Accession number KU646836) [8]. 250 
3.5. Susceptibility of LMB-1-producing isolates and kinetic properties of LMB-1. The 251 
expression of LMB-1 in E. coli Top10 resulted in increased MICs of penicillins, cephalosporins and 252 
carbapenems, but not of aztreonam (Table 1). A slight inhibition of β-lactamase inhibitors on the MICs 253 
could be detected. Of note, the MIC of cefepime was lower than that of ceftazidime and MICs of 254 
aztreonam were comparable to that of E. coli TOP 10, confirming the MBL behavior of LMB-1. 255 
As purification of LMB-1 failed despite repeated attempts in different conditions, crude lysates 256 
of E. coli TOP10 pTOPO-LMB-1 were used to determine β-lactam specific activities. It revealed strong 257 
specific activity against carbapenems, oxyimino cephalosporins and aminopenicillins (Table 3). No 258 
specific activity against aztreonam nor cefepime, as previously reported (8), could be detected. When 259 
compared to NDM-1 expressed in the same conditions, LMB-1 had slightly higher (2-fold) activity 260 
against cefoxitin, whereas the activity against carbapenems was c.a. 8-fold lower (Table3). It is 261 
important to highlight that the MIC values for carbapenems in Cf164 were lower than those obtained 262 
with E. coli Top10 carrying the natural plasmid pCf164_LMB-1 and with E. coli Top10 carrying 263 
pTOPO-LMB-1. The latter results, together with the low specific activities against carbapenems as 264 
compared to NDM-1, may explain the negative results obtained with NP Carba test, a test based on 265 
imipenem hydrolysis.  266 
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Most of these results correlate well with the results of the comparative MIC studies confirming 267 
activity of LMB-1 against aminopenicillins, ceftazidime, cefotaxime and carbapenems. However, in the 268 
comparative MIC studies, expression of LMB-1 accounted for an 8-fold increase in the MIC of 269 
cefepime, which indicates that LMB-1 does indeed present activity against cefepime. The fact that no 270 
specific activity could be detected against cefepime within 10 min may indicate that the hydrolysis rates 271 
of LMB-1 for this substrate may be very low yet the hydrolysis rate appears to have been sufficiently 272 
high to account for a substantial increase in the MIC of cefepime, or the affinity of LMB-1 for cefepime 273 
may be high enough to trap the antibiotic, which is reflected in the raise of the MIC value. 274 
3.6. Characterization of plasmids and genetic environments. PacBio assembly analysis 275 
revealed 12 contigs, two of them belonging to plasmidic DNA. The presence of two plasmids was 276 
confirmed by Kieser extraction (Figure 1). blaLMB-1 gene was inserted onto a conjugative IncA/C type 277 
plasmid of 175,712bp, pCf164_LMB-1 (accession number MH475146.1) (Figure 1), that also carried 278 
blaPER-2 gene. pCf164_LMB-1 was different from the IncFIB(K)-type pNRZ-10170-LMB-1 plasmid 279 
found in E. cloacae NRZ-10170 from Austria (accession number MH056209.1) [8] except for the 280 
immediate genetic environment of blaLMB-1 gene.  281 
The comparison of the immediate genetic environment of blaLMB-1 in pNRZ-10170-LMB-1 and 282 
in pCf164_LMB-1 revealed an identical area between a qacG gene upstream of blaLMB-1 gene and sul1 283 
gene downstream of blaLMB-1 gene (Figure 2). This genetic organization is similar to a complex class 1 284 
integron with the presence of ISCR1 element. Toleman et al. reported the mobilization of class 1 285 
integrons by ISCR1 through the transposition of ISCR1 next to the 3’ end of the class 1 integron 286 
(qac/sul genes) and the transposase misreading of the terIS sequence [21]. The segment of DNA 287 
involving the 3’ end of the class 1 integron and the 5’ end of the ISCR1 is deleted erasing the normal 288 
termination site, terIS and thereby creating and integron-ISCR1 fusion. From this point on, ISCR1 is 289 
able to mobilize the integron [21]. It is likely that the similarities observed in the genetic environment 290 
of blaLMB-1, in pNRZ-10170-LMB-1 and in pCf164_LMB-1, might be the result of blaLMB-1 gene 291 
mobilization mediated by an ISCR1, among other events. LMB-1 shares 99% sequence identity with a 292 
predicted MBL (SEI10464) from the marine bacterium R. pacifica, as previously shown [8].  293 
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IncA/C plasmids were among the earliest antimicrobial resistance-encoding plasmids identified 294 
in Gram-negative bacteria and have received attention due to their broad host range and their 295 
association with the emergence of multidrug resistance in enteric pathogens of humans and animals 296 
[22]. IncA/C plasmids are of high-molecular-weight low-copy-number and are considered responsible 297 
for the dissemination of the clinically-relevant ß-lactamase genes e.g. blaCTX-M, blaCMY, blaNDM, blaIMP, 298 
blaVIM, and blaKPC genes, among others [23,24]. In a nucleotide BLAST search for closely related 299 
plasmids to pCf164_LMB-1, two IncA/C plasmids were found, namely in, Salmonella enterica strain 300 
CFSAN064034 plasmid pGMI17-002_1 (CP028170) and in Vibrio cholerae genome assembly V. 301 
cholerae 116-17a plasmid pNDM-116-17 both isolated in India (LN831185). In addition, plasmid 302 
pCf587 harboring PER-2 (MG053108) recovered in Argentina from C. freundii 33587, also belongs to 303 
IncA/C type plasmids and is related to pCf164_LMB-1 [25]. PER-2 has been the second most prevalent 304 
ESBL, after the pandemic CTX-Ms, in Argentina, accounting for nearly 10% and 5% of the oxyimino-305 
cephalosporin resistance in K. pneumoniae and E. coli, respectively [25]. Comparative sequence 306 
analysis revealed a conserved backbone length and similar overall genetic arrangements (Figure 3). 307 
pNRZ-10170-LMB-1 was also included in the analysis, showing similarities only in the immediate 308 
environment of blaLMB-1 gene (Figure 3).  309 
The second plasmid carried by Cf164, pCf164_CTX-M-8 (accession number MN187903), was 310 
fully sequence by PacBio as a single contig. This 68,453 bp plasmid belonged to the IncM 311 
incompatibility group and encoded plasmid replication, maintenance, and transfer genes and two 312 
resistance gene regions (Figure 4). The first one contained the blaTEM-1A penicillinase and the 313 
second one of 3,560 bp, contained the blaCTX-M-8 gene bracketed by two copies of IS26 likely forming a 314 
composite transposon [2]. Overall, the nucleotide sequence of pCf164_CTX-M-8 was extremely similar 315 
to that of pKp145-11b recovered from a K. pneumoniae clinical isolate from Brazil (GenBank accession 316 
number KX118608) [26]. The differences between these two plasmids are based on the resistance genes 317 
present next to the blaTEM-1A gene. Indeed, pKp145-11b harbored a Tn1331-like element, that carried in 318 
addition to blaTEM-1A gene, three other resistance genes blaOXA-9 gene, ant(3’)-Ia gene and aac(6’)-Ib 319 
gene [26], as previously described [27]. Finally, as reported pKp145-11b had high nucleotide sequence 320 
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identity with plasmid pKp41M (accession number KY781949), another IncM plasmid carried by a K. 321 
pneumoniae isolate recovered from a parrot in Brazil [26]. To the best of our knowledge, this is the first 322 
report of blaCTX-M-8 gene carried by an IncM type plasmid reported in Argentina, suggesting that this 323 
epidemic plasmid is not only circulating amongst human and animal in Brazil, but is now also spreading 324 
to the south of the continent.  325 
4. Conclusion 326 
In conclusion, this is the first report of LMB-1, a novel MBL of sub class B3, carried by a 327 
IncA/C type plasmid. Our data suggests that R. pacifica is likely the progenitor of LMB-1, and that two 328 
independent mobilization events have occurred on two different plasmids, in two different species, and 329 
on two distantly located continents. The dissemination of the conjugative pCf164_LMB-1 represents a 330 
public health threat as it combines a prevalent ESBL gene (blaPER-2) with a difficult to detect 331 
carbapenemase gene and that both genes are harbored by a broad-spectrum and conjugative IncA/C 332 
plasmid that may spread to many human pathogens.  333 
LMB-1 displays hydrolytic activities against most ß-lactams, especially carbapenems and 334 
cephalosporins, that are important antimicrobial agents for the treatment of severe nosocomial 335 
infections caused by Enterobacterales. Even tough in the susceptibility range, animal models of 336 
infections are required to evaluate whether carbapenems may be a suitable therapeutic option. The fact 337 
that molecular assays, nor ResFinder, nor immunochromatography tests failed to identify this novel 338 
MBLs, and that biochemical tests gave inconsistent results may lead to silent spread of this type of 339 
enzyme. Thus, epidemiological studies to evaluate the extend of the dispersion of LMB-1 in Europe and 340 
the Americas should be undertaken.  341 
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Table 1 MIC values of β-lactams for C. freundii 164, E. coli TOP10 pTOPO-CMY-150, E. coli 434 
TOP10 pTOPO-CMY-2, E. coli TOP10 pN-LMB-1, E. coli TOP10 pTOPO-LMB-1 and E. coli 435 
TOP10. 436 
  MIC (µg/mL) 
Antibiotic 
C. freundii 
164 
E. coli TOP10 
E.coli 
TOP10 
(pTOPO-
CMY-150) 
(pTOPO-
CMY-2) 
(pCf164_ 
LMB-1) 
 (pTOPO-
LMB-1) 
Amoxicillin >256 >256 >256 >256 >256 2 
Amoxicillin + CLAa 64 64 32 >256 24 2 
Cefotaxime >32 >32 8 >32 4 0.06 
Ceftazidime 128 >256 24 >256 48 0.12 
Cefepime 2 0.5 0.125 8 0.38 0.023 
Imipenem 0.5 0.38 0.24 1.5 0.75 0.25 
Meropenem 0.094 0.047 0.023 0.8 0.25 0.016 
Ertapenem 0.064 0.047 0.012 0.5 0.19 0.003 
Temocillin 64 24 16 >1024 512 4 
Aztreonam 32 32 3 >256 0.064 0.047 
aCLA, clavulanic acid (2 µg/ml) 437 
438 
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 439 
Table 2 . Kinetic parameters of CMY-150 and CMY-2. 440 
 441 
Substrate 
Km(µM) 
 
kcat(s-1) 
 
kcat/Km (mM-1 s-1) 
CMY-150 CMY-2 
 
CMY-150 CMY-2 
 
CMY-150 CMY-2 
Ampicillin 55 16 
 
0.30 3.2 
 
5.4 204 
Ceftazidime 13 15 
 
0.04 0.05 
 
3.1 3.3 
Imipenem 3.7 2.5 
 
0.02 0.02 
 
5.8 9.6 
Aztreonam NHa NH 
 
NH NH 
 
- - 
a No hydrolysis 442 
443 
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Table 3. Specific activities for β-lactamases NDM-1 and LMB-1. 444 
Antibiotic 
Specific Activity (mU/mg) 
NDM-1 LMB-1 
Cefalotine 0.41 0.44 
Cefoxitine 0.44 0.81 
Ceftazidime 0.38 0.24 
Imipenem 7.42 0.88 
Meropenem 5.95 0.88 
Ertapenem 6.55 0.66 
Experiments were done in triplicate. Error rates were within 10% 445 
446 
 21 
 447 
Figure legends  448 
 449 
Figure 1. Plasmid extraction. Migration of the extracted pCf164_LMB-1 from the Cf164 (WT) and 450 
the transconjugant E. coli J53 (Tc). M, marker. 451 
 452 
Figure 2. Genetic environment of blaLMB-1. Comparison of the genetic environment of blaLMB-1 gene 453 
presents in Cf164_LMB-1 with the environment of blaLMB-1-like sequence in Rheinheimera pacifica 454 
and blaLMB-1 gene in pNRZ-10170-LMB-1. Truncated ORFs are indicated by ∆.  455 
 456 
Figure 3. Comparative genome analyses of several IncA/C group plasmids. Structural comparison of 457 
pCf164_LMB-1 with those of the most similar IncA/C group plasmids and pNRZ-10170-LMB-1.  458 
 459 
Figure 4. Plasmid sequence schematic representation. Major structural features of the plasmids 460 
pKp145-11b (KX118608) and pCf164_CTX-M-8 (MN1879903). Common structures are 461 
highlighted in gray. Resistance genes and boxed in black. The blaCTX-M-8 composite transposon is 462 
also indicated. 463 
 464 
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